There is a risk of fatal reactivation of hepatitis B virus (HBV) among HBs-Ag positive patients undergoing hematopoietic stem cell transplantation (HSCT).
1 However, active antiviral therapy may modify the natural history of HBV infection during immunosuppression and immune recovery following HSCT.
We report a case of an HBs-Ag positive patient who, despite lamivudine prophylaxis, developed a severe HBV reactivation after a reduced intensity conditioning (RIC) HSCT, which was finally controlled by adefovir.
A 21-year-old woman presented with a refractory relapse of acute myeloid leukemia (AML), 7 months after an autologous HSCT. She received as a salvage therapy an allogeneic unrelated RIC HSCT that induced a complete remission.
At the time of AML diagnosis, the patient was diagnosed as an HBV chronic carrier, by the serum detection of HBs antigen and a positive HBV DNA at 363 000 copies/ml. Despite normal liver functions, Lamivudin (LMV) was given (100 mg/day) to prevent severe HBV reactivation under therapy. HBV viral load rapidly decreased, and was below the limits of detection (200 copies/ml) at the time of AML relapse.
Viral load started to rise immediately after salvage chemotherapy and intensified after allogeneic HSCT, whereas the patient was still under LMV. At day 71 post-HSCT, reactivation of HBV was confirmed by the dramatic increase of the HBV-DNA load to over 200 Â 10 6 copies/ml, with elevated aminotransferases over 10-fold the normal values and increased total bilirubin. LMV escape was documented by the demonstration of resistance mutations in the YMDD motif of HBV polymerase. LMV was then switched to the new nucleotide analogue Adefovir Dipivoxil (ADV) (10 mg/day). HBV-DNA load dropped to 3.3 Â 10 6 copies/ml after 4 weeks and persistently decreased, becoming undetectable after 15 months of ADV (Figure 1 ), whereas the patient was still in complete remission. No side effect of ADV was observed.
The use of ADV was recently reported for HBV subfulminant reactivation under chemotherapy. 2 We describe here the efficacy of this drug in a highly immunosupressed patient to circumvent resistance to LMV. This observation confirms that chronic infection with replicative HBV is not a contraindication for profound immunosuppressive therapies such as HSCT, if an efficient control of HBV replication is provided by antiviral therapy. LMV has already been used for this indication, 3,4 but the favourable resistance profile of ADV compared to LMV 5 may bring this drug forward as a good alternative for preventing HBV reactivation in long lasting immunosuppression situations. These patients should be closely monitored for viral load increase and viral resistance, especially during repeated courses of chemotherapy. 
